Article

A novel rat model for chemotherapy-induced alopecia

Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Clinical and Experimental Dermatology (Impact Factor: 1.09). 04/2012; 37(3):284-9. DOI: 10.1111/j.1365-2230.2011.04239.x
Source: PubMed

ABSTRACT

More than half of all people diagnosed with cancer receive chemotherapy, and approximately 65% of these develop chemotherapy-induced alopecia (CIA), a side-effect that can have considerable negative psychological repercussions. Currently, there are very few animal models available to study the mechanism and prevention of CIA.
To develop a clinically relevant adult rat model for CIA.
We first tested whether neonatal pigmented Long-Evans (LE) rats developed alopecia in response to the chemotherapeutic agents etoposide and cyclophosphamide. We then determined whether the rats developed CIA as adults. In the latter experiment, rat dorsal hair was clipped during the early telogen stage to synchronize the hair cycle, and starting 15 days later, the rats were treated with etoposide for 3 days.
Neonatal LE pups developed CIA in response to etoposide and cyclophosphamide, similar to other murine models for CIA. Clipping of the hair shaft during early telogen resulted in synchronized anagen induction and subsequent alopecia after etoposide treatment in the clipped areas only. Hair follicles in the clipped areas had the typical chemotherapy-induced follicular dystrophy (dystrophic catagen). When the hair in the pigmented alopecic areas regrew, it had normal pigmentation.
A novel, pigmented adult rat model has been established for CIA. By hair-shaft clipping during early telogen, synchronized anagen entry was induced, which resulted in alopecia in response to chemotherapy. This is the first clinically relevant adult rat model for CIA, and will be a useful tool to test agents for the prevention and treatment of CIA.

Download full-text

Full-text

Available from: Tongyu C. Wikramanayake, Apr 03, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Discovery of novel drugs, treatments, and testing of consumer products in the field of dermatology is a multi-billion dollar business. Due to the distressing nature of many dermatological diseases, and the enormous consumer demand for products to reverse the effects of skin photodamage, aging, and hair loss, this is a very active field. Areas covered: In this paper, we will cover the use of animal models that have been reported to recapitulate to a greater or lesser extent the features of human dermatological disease. There has been a remarkable increase in the number and variety of transgenic mouse models in recent years, and the basic strategy for constructing them is outlined. Expert opinion: Inflammatory and autoimmune skin diseases are all represented by a range of mouse models both transgenic and normal. Skin cancer is mainly studied in mice and fish. Wound healing is studied in a wider range of animal species, and skin infections such as acne and leprosy also have been studied in animal models. Moving to the more consumer-oriented area of dermatology, there are models for studying the harmful effect of sunlight on the skin, and testing of sunscreens, and several different animal models of hair loss or alopecia.
    Full-text · Article · Jan 2013 · Expert Opinion on Drug Discovery
  • [Show abstract] [Hide abstract]
    ABSTRACT: One of the most common and distressing side effects of cancer therapy is chemotherapy-induced alopecia (CIA). Approximately 65% of patients receiving anti-neoplastic therapies experience some degree of alopecia. The study of CIA had been hampered by the lack of suitable animal models; in this regard, the first animal models used to study CIA were impractical and difficult to extrapolate to the humans. In recent years, the development of the young rat models and the mouse model of CIA opened new avenues to the investigation and understanding of the mechanisms of CIA. However, there has been much controversy as to which model is more suitable to study the histopathology and molecular mechanisms of CIA. The young rat model has been employed due to the fact that 100% of the pelage hair follicles are in the growth phase during postnatal morphogenesis, therefore mimicking the human scalp where 90% of the hair follicles are undergoing anagen (active growth phase of the hair cycle) at any given time. In contrast, in the adult mouse and rat models, anagen synchronization needs to be induced by depilation or shaving to mimic the human scalp. These models have been extensively used in the search for protective agents against CIA. In this chapter, we will compare and contrast the different models and review the state-of-the-art findings in terms of animal models and protective agents. © 2013 by Nova Science Publishers, Inc. All rights reserved. All rights reserved.
    No preview · Article · Mar 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Conventional chemotherapy leads to multiple adverse mucocutaneous complications such as oral mucositis, alopecia, ocular toxicity, and onycholysis. Limited pharmacologic interventions are available for preventing these clinical problems. This study aimed to critically review the role of cryotherapy (regional hypothermia) for alleviating these adverse symptoms. A narrative review was performed, with an emphasis on randomized controlled trials. A comprehensive search using PubMed, Ovid, Embase, and MEDLINE(®) was completed. References of all cited articles also were reviewed. Data from the review were composed of articles published between 1970 and May 2013. Available evidence suggests that regional hypothermia decreases the burden of chemotherapy-related oral mucositis, alopecia, ocular toxicity, and onycholysis. The major limitations of studies include the absence of blinded control groups and variable clinical end points. Regional hypothermia decreases the burden of these four chemotherapy-induced complications and is well tolerated. More research is needed to determine what subgroups of cancer patients are most likely to respond to different types of regional hypothermia, the ideal duration of cooling needed, and further improve the ease of use of the cooling devices.
    No preview · Article · Nov 2013 · Journal of pain and symptom management
Show more